Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 11/20 | 0.35 |
| ▸ | BTK | Q06187 | 11/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22713064 | 0.78 | KDM5B (0.36) | ACHE | |
| SCHEMBL27550332 | 0.77 | THRB (0.40) | JAK3BTKKDM4CTHRB | |
| SCHEMBL11001892 | 0.74 | ACHE (0.48) | ACHEJAK3BTKKDM4CKDM4E | |
| SCHEMBL27074350 | 0.73 | CYP1A2 (0.49) | KDM4E | |
| SCHEMBL27965773 | 0.72 | CHRNB2 (0.43) | — | |
| SCHEMBL25477789 | 0.71 | LOXL2 (0.39) | ACHEKDM4CKDM4EKDM4AKDM5C | |
| SCHEMBL28925341 | 0.70 | ACHE (0.44) | ACHEJAK3BTKKDM4CTHRB | |
| SCHEMBL21050072 | 0.70 | KMT2A (0.44) | ACHE | |
| SCHEMBL24686656 | 0.67 | EIF2AK4 (0.39) | ACHEKDM4CKDM4EKDM4AKDM5C | |
| SCHEMBL3295288 | 0.66 | ACHE (0.57) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | ACHE 2103/4885JAK3 981/4885BTK 2463/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | ACHE 3505/4885JAK3 2517/4885BTK 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.